EWA
RAPP

EverSource Wealth Advisors’s Rapport Therapeutics RAPP Stock Holding History

EverSource Wealth Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.13K Hold
147
– – ﹤0.01% 3186
2026
Q1 		$4.6K Buy
147
+32
+28% +$900 ﹤0.01% 3306
2025
Q4 		$3.49K Hold
115
– – ﹤0.01% 3270
2025
Q3 		$3.42K Buy
115
+30
+35% +$535 ﹤0.01% 3311
2025
Q2 		$966 Buy
85
+26
+44% +$276 ﹤0.01% 3748
2025
Q1 		$592 Buy
59
+58
+5,800% +$753 ﹤0.01% 3403
2024
Q4 		$18 Buy
+1
New +$22 ﹤0.01% 3716

Other funds holding RAPP

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

EverSource Wealth Advisors's RAPP Position: Q2 2026 in Review

EverSource Wealth Advisors held its Rapport Therapeutics (RAPP) position steady in Q2 2026 at 147 shares worth $6.13K. The position accounts for ﹤0.01% of the portfolio, ranked #3186.

EverSource Wealth Advisors first reported a position in RAPP in Q4 2024 and has held it in 7 quarters since. 31 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • EverSource Wealth Advisors held 147 shares of Rapport Therapeutics worth $6.13K as of Q2 2026.
  • EverSource Wealth Advisors left its Rapport Therapeutics share count unchanged in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3186 holding.
  • EverSource Wealth Advisors first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 31 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.